Teva: Patented Method For Reducing Cardiovascular Events Is Obvious
ALEXANDRIA, Va. — Various claims of a patented method of co-administering “familiar” doses of rivaroxaban and aspirin should be canceled, Teva Pharmaceuticals USA Inc. tells the Patent Trial and Appeal Board...To view the full article, register now.
Already a subscriber? Click here to view full article